|
Welcome to Octapharma!
Octapharma, a Swiss-based company, is an independent, global plasma fractionation specialist. Its core business is the development, production and sale of high quality plasma derivatives.
The company has grown to 1,800 employees in 27 countries since its founding in 1983. Octapharma owns four modern, state-of-the-art production facilities in
Austria
,
France
,
Sweden
and
Mexico
. Since 2005 Octapharma has also operated the NSTOB plant in Springe
Germany
. Sales turnover in 2006 exceeded Euro 572 million.
Octapharma continues to grow and invest heavily in the future. Profits, are mainly channelled into R&D and further improvements and expansion of Production.
In the highly demanding market of life-saving plasma products, company success is only possible through reliable product quality and a proven safety record.
Octapharma Mission
Since the foundation of Octapharma in 1983, the company has establlished a clear and consistent mission: for the safe and optimal use of plasma.
This mission statement has stood the test of time and has driven our activities in the last 25 years.
Over the past six years, in addition to our plasma-based activities, Octapharma has dedicated increasing resources to recombinant product research and development based on the use of human cell lines.
Our recombinant R&D department in Sweden has completed pre-clinical toxicology testing in animals and is preparing for the manufacture of product for human testing.
This unique approach sets us apart from other companies whose recombinant products are based on animal (murine) cells.
To better reflect this significant milestone and the future direction of Octapharma, our new mission statement as of May 2007 is “for the safe and optimal use of human proteins”.
For the safe and optimal use of human proteins
Octapharma respects donated human plasma as a scarce and valuable resource. By using leading edge, validated viral inactivation and purification technologies Octapharma aims to achieve the highest production yields and produce products with the highest possible safety margins.
|
|
 |
|
|
